PharmAthene, Inc.  

(Public, NYSEMKT:PIP)   Watch this stock  
Find more results for NYSEAMEX:PIP
+0.06 (3.77%)
Real-time:   12:39PM EST
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 1.54 - 1.65
52 week 1.19 - 2.59
Open 1.54
Vol / Avg. 32,555.00/237,973.00
Mkt cap 105.90M
P/E     -
Div/yield     -
EPS -0.21
Shares 63.37M
Beta 1.65
Inst. own 41%
Mar 9, 2015
Q4 2014 PharmAthene Inc Earnings Release (Estimated) Add to calendar
Jan 20, 2015
PharmAthene Inc at Noble Financial Equity Conference
Nov 6, 2014
Q3 2014 PharmAthene Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -480.90% -65.42%
Operating margin -415.19% -60.51%
EBITD margin - -59.49%
Return on average assets -96.26% -58.77%
Return on average equity -128.16% -123.29%
Employees 52 -
CDP Score - -


Suite #450, One Park Place
United States - Map
+1-410-2692600 (Phone)
+1-410-2692601 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


PharmAthene, Inc. is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical threats. The Company�s biodefense portfolio of product candidates include SparVax, a second generation recombinant protective antigen (rPA) anthrax vaccine; Valortim, a fully human monoclonal antibody for the prevention and treatment of anthrax infection, and rBChE (recombinant butyrylcholinesterase) bioscavanger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides. SparVax is a second generation, rPA anthrax vaccine designed to protect against inhalational anthrax, the most lethal form of B. anthracis infection in humans. Valortim is a fully human monoclonal antibody designed to protect against and treat human inhalational anthrax, as both post-exposure prophylaxis and post-exposure therapy.

Officers and directors

Mitchel B. Sayare Ph.D. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Eric I. Richman President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Linda L. Chang Chief Financial Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Francesca M. Cook Senior Vice President - Policy and Government Affairs
Age: 49
Bio & Compensation  - Reuters
Wayne Morges Ph.D. Senior Vice President - Regulatory Affairs and Quality
Age: 67
Bio & Compensation  - Reuters
Arthur Y. Elliott Ph.D. Acting Chief Scientific Officer
Age: 78
Bio & Compensation  - Reuters
John M. Gill Independent Director
Age: 62
Bio & Compensation  - Reuters
Brian A. Markison Independent Director
Age: 55
Bio & Compensation  - Reuters
Joel W. McCleary Independent Director
Age: 65
Bio & Compensation  - Reuters
Jeffrey W. Runge M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters